| abstract |
For example, the compounds of formula (I), or pharmaceutically acceptable salts, derivatives, solvates, isomers, isomers thereof, used as OGA inhibitors in the treatment of various conditions and diseases including neurodegenerative disorders. Variants, N-oxides, esters, prodrugs, isotopes or protected forms are disclosed. [Selection] Figure 1 |